Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view

Pharmacogenomic biomarker availability of Hungarian Summaries of Product Characteristics (SmPC) was assembled and compared with the information in US Food and Drug Administration (FDA) drug labels of the same active substance (July 2019). The level of action of these biomarkers was assessed from The...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnai, Reka, Szabo, Istvan, Tarlos, Greta, Szentpeteri, Laszlo Jozsef, Sik, Attila, Balogh, Sandor, Sipeky, Csilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253355/
https://www.ncbi.nlm.nih.gov/pubmed/31787752
http://dx.doi.org/10.1038/s41397-019-0123-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253355/
https://www.ncbi.nlm.nih.gov/pubmed/31787752
http://dx.doi.org/10.1038/s41397-019-0123-z

Ejemplares similares